HealthDay News — Recommendations for the diagnosis and management of severe acquired aplastic anemia are presented in a clinical practice guideline issued by the American Society of Hematology and ...

Add Yahoo as a preferred source to see more of our stories on Google. Dec. 8 (UPI) --The U.S. Food and Drug Administration on Monday announced the approval of the first hematopoietic stem cell ...

A Prescription Drug User Fee Act target date of December 10, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

What Is Omisirge, and Why Does It Matter? Omisirge (omidubicel-onlv) is a type of cell therapy made from umbilical cord blood. It helps your body make new blood cells after a stem cell transplant.

Holly Hill Academy celebrates student’s return with parade after medical clearance ...

Please provide your email address to receive an email when new articles are posted on . Prior trials established the role of haploidentical BMT for severe aplastic anemia. Two trials underway have the ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

DUBLIN, IRELAND AND LONDON, UK = / ACCESS Newswire / December 8, 2025 / Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation today ...

The FDA has approved omidubicel-onlv (Omisirge, Gamida Cell Ltd.) as the first hematopoietic stem cell transplant therapy for patients with severe aplastic anemia (SAA). Specifically, omidubicel is ...

DUBLIN, IE AND LONDON, UK / ACCESS Newswire / December 5, 2025 / Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., a leader in cell therapy innovation announces that it ...